)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Bacil Pharma
Bacil Pharma (524516) investor relations material
Bacil Pharma Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary14 Oct, 2026
Executive summary
Q2 FY26/27 revenue was ₹9.18 lakh; H1 revenue was ₹18.09 lakh versus ₹105.74 lakh in H1 FY25/26.
H1 standalone profit after tax was a loss of ₹2.59 lakh; consolidated loss after tax was ₹8.83 lakh.
Financial highlights
Q2 consolidated PBT was a loss of ₹2.99 lakh and H1 consolidated PBT was ₹3.65 lakh; comparative H1 FY25/26 PBT was ₹91.20 lakh.
H1 OCI gain on fair valuation of financial assets was ₹48.01 lakh; consolidated total comprehensive income was ₹39.18 lakh.
Standalone H1 total comprehensive income was ₹45.42 lakh, including ₹48.01 lakh of OCI fair-valuation gains.
Segment performance
One reportable primary pharmaceutical business segment under Ind AS 108.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Bacil Pharma
- Quarterly profit after tax reached ₹30.12 lakhs on flat revenue of ₹8.91 lakhs.524516
Q1 26/27 - FY26 saw higher revenue but a net loss due to investment valuation, with operations yet to restart.524516Q4 25/26
- Quarterly net profit rose to ₹3.92 lakhs with improved revenue and clean auditor review.524516Q3 25/26
- Sharp drop in revenue and profit, with auditors issuing a disclaimer due to major uncertainties.524516Q2 25/26
- Profit rebounded sharply in Q1 FY26, but auditor raised concerns over fund application.524516Q1 25/26
- Q2 FY25 saw a sharp turnaround to profit and revenue growth, but loan recoverability remains uncertain.524516Q2 24/25
- Quarterly loss before tax, but profit after OCI; auditor flags loan recoverability concerns.524516Q1 24/25
- FY25 saw significant revenue and profit growth, but loan recoverability remains a concern.524516Q4 24/25
- Net loss in Q3 FY25, no core revenue, and auditor flags loan recoverability concerns.524516Q3 24/25
Next Bacil Pharma earnings date
Q3 26/2712 Feb, 2027
Bacil Pharma
Next Bacil Pharma earnings date
Q3 26/2712 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Bacil Pharma Limited is a pharmaceutical company engaged in the manufacturing and marketing of medicinal formulations. The company produces a range of pharmaceutical products, including tablets, capsules, and other dosage forms, serving various therapeutic segments. Its operations may include contract manufacturing and supply to domestic markets. The company is headquartered in Mumbai, India, and its shares are listed on the BSE.